Archive for the ‘Inflammation’ Category

‘Brain on Fire’ Cases Epitomize Benefits of Dual-trained Doctors

https://www.utsouthwestern.edu/newsroom/articles/year-2018/brain-on-fire.html?fbclid=IwAR0mMorVXdusRc88gqePYP0J5ERh0Jx_R3vpvqdPcbSctwsyTjk_CSNh_j4

‘Brain on Fire’ cases epitomize benefits of dual-trained doctors

November 29, 2018| Media Contact: James Beltran

Rare program looks to expand blended expertise in psychiatry, neurology

https://player.vimeo.com/video/302889376

(Video here)

DALLAS – Nov. 29, 2018 – Glen Carter woke up on a white linen bed inside a psychiatric unit, the excruciating pain in his shoulder mingling with a growing sense of alarm.

How had he arrived here? What was wrong with his shoulder?

Mr. Carter later learned he had driven to UT Southwestern for help and had been acting erratically – hearing voices, seeing visions, and sputtering to doctors thoughts of his imminent death.

“I had no recollection of any of it,” said Mr. Carter, 58.

Glen Carter (left) had been a pillar of stability for his children (middle) and wife Janet (far right) until last year when he began behaving increasingly erratic. A UT Southwestern doctor determined Mr. Carter was not schizophrenic but instead had a rare autoimmune disorder.

The uncharacteristic behavior indicated a potential case of schizophrenia, yet his doctor noticed a few factors that didn’t add up. For instance, the longtime husband and father of two had no history of mental illness and had a severely dislocated shoulder usually only seen after major trauma such as car accidents or seizures.

The doctor ordered X-rays, brain imaging, and other tests that confirmed his suspicion: Mr. Carter did not have schizophrenia but rather a rare form of brain inflammation that would not have been reversed with antipsychotic medication.

“The shoulder was a big clue, then we noticed a bite mark on the side of his tongue that indicated he probably had a seizure,” said Dr. Robert Weir, who last December diagnosed Mr. Carter with a neurological condition called autoimmune encephalitis. “He responded remarkably well within a day of putting him on high-dose steroids, and he was soon able to resume his life as normal.”

Mr. Carter was the beneficiary of a blend of medical training that until recently was only offered to a select group of doctors on the East Coast: combined certification in psychiatry and neurology. Following a lengthy national moratorium that prevented medical schools from adding the dual training, the country’s newest such program at UT Southwestern represents a modest but notable step in filling a lingering national shortage of physicians skilled in the two fields.

The effects of the shortage are sometimes as benign as a slightly delayed diagnosis, but in extreme cases, patients may bounce from clinic to clinic and meander through a series of misdiagnoses and ineffective treatments, wreaking havoc on their personal and professional lives. A similar ordeal was publicized in the autobiography and subsequent film “Brain on Fire,” the story of a journalist who was mislabeled as having a primary psychotic disorder until she – like Mr. Carter – was diagnosed with autoimmune encephalitis.

Coming up on the one-year anniversary of Mr. Carter’s diagnosis, the bond broker is enjoying a holiday season much different than the last, when his normally joyous time with family and friends was riddled with emotional distress and medical mystery.

Dr. Robert Weir helped develop the curriculum for UT Southwestern’s combined residency program for neurology and psychiatry.

Dr. Weir is encouraged to hear about the impact his expertise had on Mr. Carter, who no longer needs treatment for the condition and hasn’t missed any significant time from work this year.

“The term ‘mental illness’ is thrown around a lot and frequently misused,” said Dr. Weir, who helped develop the curriculum for UT Southwestern’s combined residency program for neurology and psychiatry. “People with certain conditions are sometimes misdiagnosed and undertreated because we can’t tell them on a biomolecular level what’s really happening to them.”

Filling the gap

Only five medical centers across the country offer the combined training, each one producing less than a handful of doctors a year – not nearly enough to cover the country’s vast expanse of patients who could benefit from their integrated skills.

UT Southwestern took its first step to create the curriculum after the national board that certifies these programs lifted a five-year moratorium on submitting applications in 2014, due to a change in certification protocol.

The addition of the Dallas-based program – the only one approved since the freeze was lifted – will only slightly help the overall physician numbers. However, it will likely play a crucial role in expanding access for patients who don’t live out East. Other programs are at places such as Brown University and the University of Massachusetts.

“That’s one of the reasons why we’re so excited about creating this combined residency,” said Dr. Adam Brenner, Co-Director of UT Southwestern’s program. “The odds are greater that doctors will stay near where they’re trained, which is important because this training hasn’t existed in Texas and most other parts of the country.”

Dr. Adam Brenner, Professor of Psychiatry

UT Southwestern offers a six-year combined residency for doctors that includes a clinical track dividing time between neurology and psychiatry. The expertise has been helpful in diagnosing patients like Mr. Carter with rare autoimmune disorders, as well as a number of other conditions with overlapping symptoms, including epilepsy, Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease.

The creation of the country’s newest program comes amid a growing push to utilize neurology tools in psychiatry, including an award-winning approach to objectively diagnose and treat different types of psychoses through evaluating neural images and electrical activity in the brain, among other strategies. National clinical trials are also providing early glimpses into how these high-tech tools – including magnetic seizure therapy – may impact treatment in depression and psychosis.

“It’s an exciting time to be involved in psychiatry and neurology,” said Dr. Weir, who is in the fourth year of the combined residency program he spearheaded. “Our technology is finally catching up to our curiosity.”

‘A desperate need’

Mr. Carter had been a pillar of stability for his family. The breadwinner, the caring husband, the father who helped raise two children.

Then his life unraveled last year when he began having hallucinations. He took anxiety medications, but his condition only worsened in the following months. On one occasion he thought he was having a heart attack. Another time he asked his wife if she could hear God talking to her too.

“He was asking to go to the hospital, but even after a few trips to the emergency room we couldn’t put our finger on it,” said Janet Carter, Mr. Carter’s wife of 28 years. “This was nothing like Glen Carter.”

Her husband reached a breaking point on Dec. 8, 2017. Shortly after arriving at work, he drove himself to UT Southwestern and was admitted into the psychiatric unit, where Dr. Weir was on rotation that month.

Glen (left) and Janet Carter had tried for months last year to pinpoint the reason for Mr. Carter’s increasingly erratic behavior. He was eventually diagnosed with an autoimmune disorder at UT Southwestern.

Dr. Weir recalls Mr. Carter acting strangely, taking his clothes off and putting them in the shower, predicting his own death within 12 hours, and hearing voices in his head.

“None of that is very odd with psychotic behavior, but some things just didn’t add up,” Dr. Weir said. “He had been previously healthy and had a very abrupt change in behavior.”

Mr. Carter’s injured shoulder, likely dislocated during a seizure, set Dr. Weir on the path to solve the mystery that had perplexed the family for months. He was not schizophrenic after all. He suffered from autoimmune encephalitis, which occurs when the body’s immune system attacks healthy brain cells and inflames the brain, sometimes prompting psychiatric symptoms.

Mr. Carter was given steroids – a treatment that normally could be harmful to a hallucinating patient – and was back to normal within several days.

“I was in a desperate need,” Mr. Carter said during a recent visit to UT Southwestern to share his story. “I honestly don’t know how I got through this without losing my dignity. … We’re very grateful for what took place here.”

Growing demand

Mr. Carter’s case is not unique.

One study indicates at least 3 to 5 percent of psychotic behavior first seen in patients is due to an autoimmune condition.

How many of those patients are accurately diagnosed the first time and put on proper treatment is more difficult to determine.

Although awareness of autoimmune encephalitis has improved since the “Brain on Fire” book published in 2012, some doctors anticipate the demand will only grow for combined training in neurology and psychiatry.

“These two specialties have an area of overlap,” said Dr. Brenner, Professor of Psychiatry at UT Southwestern’s Peter O’Donnell Jr. Brain Institute. “And patients with conditions in this overlap sometimes really benefit from having one doctor who can encompass the whole picture. I’m confident that when Dr. Weir and others finish their residency, other medical students will see their work and want to follow in their path.”

About UT Southwestern Medical Center

UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institution’s faculty has received six Nobel Prizes, and includes 22 members of the National Academy of Sciences, 17 members of the National Academy of Medicine, and 15 Howard Hughes Medical Institute Investigators. The faculty of more than 2,700 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide care in about 80 specialties to more than 105,000 hospitalized patients, nearly 370,000 emergency room cases, and oversee approximately 2.4 million outpatient visits a year.

___________________

**Comment**

This is wonderful news. There has been a dearth of specialized doctors qualified to diagnose this condition which has been known to be a part of the Lyme/MSIDS picture: https://madisonarealymesupportgroup.com/2017/10/01/panspandas-steroids-autoimmune-disease-lymemsids-the-need-for-medical-collaboration/

Within this link boy’s Lyme Disease Morphs into Autoimmune encephalopathy. It took 10 years and 20 doctors to find out 12-year-old Patrik had Lyme disease. Just 4 months later the doctors discovered he also has a condition where his immune system attacks his brain. Dr. Souhel Najjar, Cahalan’s doctor, heroically saves the day again. (Video within link)

According to a prominent Wisconsin LLMD, 80% of his patients have tick borne illness along with PANS/PANDAS as well as Autism. If a child has an abrupt change in behavior such as the man in the main article, please consider this and get him to someone trained in this area.

https://madisonarealymesupportgroup.com/2018/02/20/mysterious-disease-where-the-body-attacks-the-brain-more-common-than-initially-thought/

The treatment for autoimmune encephalitis can vary based on the trigger, but timing is always key. If doctors treat whatever is triggering the condition, many people with the disease can go on to lead fairly normal, full lives.

For more:

https://madisonarealymesupportgroup.com/2017/10/08/misdiagnosed-how-children-with-treatable-medical-issues-are-mistakenly-labeled-as-mentally-ill/

https://madisonarealymesupportgroup.com/2018/07/28/stories-of-pandas/

https://madisonarealymesupportgroup.com/2018/11/06/diagnosing-treating-autoimmune-encephalitis-in-patients-with-persistent-lyme-symptoms/

https://madisonarealymesupportgroup.com/2018/10/10/pans-pandas-awareness/

Category:

Activism, Inflammation, Lyme, Psychological Aspects, Treatment

Medical Cannabis Superior to Opioids for Chronic Pain, Study Finds

http://www.greenmedinfo.com/blog/medical-cannabis-superior-opioids-chronic-pain-study-finds?

“© [Nov 4, 2018] GreenMedInfo LLC. This work is reproduced and distributed with the permission of GreenMedInfo LLC. Want to learn more from GreenMedInfo? Sign up for the newsletter here http://www.greenmedinfo.com/greenmed/newsletter.”

Sufferers of chronic pain have been faced with a perilous decision—risk a crippling addiction to opioids or find a way to live with the pain. A new clinical study has focused on medical cannabis as an alternative to opioids, and the results may be a turning point towards a safe, plant-based option for easing pain

A new study published in the European Journal of Internal Medicine represents hope for millions of sufferers of chronic pain. Researchers at the Cannabis Clinical Research Institute at Soroka University Medical Center, and Ben-Gurion University of the Negev (BGU), found that medical cannabis can significantly reduce chronic pain without adverse effects, particularly among adults aged 65 and older. Use of cannabis, aka medical marijuana, was found to be both safe and effective for elderly patients experiencing pain because of another medical condition, such as cancer, multiple sclerosis, Parkinson’s disease, Crohn’s disease, ulcerative colitis, and post-traumatic stress disorder.

One of the head researchers in this study, Prof. Victor Novack, M.D., is a professor of medicine in the BGU Faculty of Health Sciences (FOHS), as well as BGU’s Chair in Internal Medicine. He also heads the Soroka Cannabis Clinical Research Institute. According to Prof. Novack, M.D.:

“Older patients represent a large and growing population of medical cannabis users, [yet] few studies have addressed how it affects this particular group, which also suffers from dementia, frequent falls, mobility problems, and hearing and visual impairments.”[1]

The study surveyed 2,736 patients aged 65 years and older, at the inception of medical cannabis treatment, and throughout the 33-month study period. Surveys indicated the most common reasons for using cannabis were pain (66.6%) and cancer (60.8%). Methods of ingestion included cannabis-infused oils and smoking or vaporizing the herb. After six months of cannabis therapy, researchers provided a follow-up questionnaire which sought to determine any changes to pain intensity and quality of life, as well as any adverse events that were experienced. 901 of the original respondents replied.

After 6-months of medical marijuana treatment (all statistics are +/-):

94% reported an improved overall condition, and a 50% reduction in pain
60% reported improved quality of life, from “bad” or “very bad” to “good” or “very good”
70% reported moderate to significant improvement in their condition
20% of respondents stopped using opioids or reduced their dose

Notably, the most common side effects reported were mild: dizziness (9.7%) and dry mouth (7.1%), a far cry from the high-percentage of opioid-related deaths that are linked to chronic pain.[2] BGU researchers believe that utilizing cannabis may decrease the use of other prescription medications, including opioids, and encourage further research into this plant-based alternative, especially as it relates to an aging population.

Chronic pain is a problem that affects an estimated 100 million Americans.[3] It is also one of the most significant public health problems in the United States, with an estimated cost to society of $560-$635 billion annually, an amount equal to about $2,000 for every person living in the U.S.[4] Meanwhile, the nation’s growing opioid epidemic sees 1 of every 550 chronic opioid users dying within three years of their first opioid prescription.[5] While natural alternatives to deadly opiates are rarely offered by medical doctors, medical marijuana may be the drug that bridges this senseless gap. Research is beginning to mount that shows more promise than the medical establishment can long ignore.

Neuropathy is a type of chronic pain that presents as tingling and numbness in the hands and feet, often due to nerve damage from complications of cancer or diabetes, among other causes. A 2017 meta-analysis of prior studies on neuropathy found that cannabis, particularly selected isolates called cannabinoids, can provide analgesic benefit in patients with chronic neuropathy. Cannabis can also be used as an adjunct to other pain therapies, potentially lowering the amount of dangerous synthetic medication that is required to relieve pain. A recent study on the Opioid-Sparing Effect of Cannabinoids found that when cannabinoids were administered with opioids, specifically morphine, nearly four times less morphine was needed to achieve the same analgesic effect. This presents further evidence for cannabis as a means of reducing cases of opiate dependency and death.

While the politics of cannabis are exceedingly complex, the truth of this miraculous plant is becoming increasingly obvious: it heals the human body. The fact that it does so without the need for a black-box warning of Serious Adverse Events ensures that cannabis is the future of medicine. While clinical studies in the United States have been impeded due to cannabis’s classification as a Schedule One Controlled Substance (meaning the substance has no medicinal value), other countries have taken the lead. A UK study seeking to reduce chronic pain in advanced cancer patients not fully relieved from use of opioids, found that a cannabis extract composed of THC (Tetrahydrocannabinol) and CBD (Cannabidiol), two of the active constituents in cannabis, reduced pain by more than 30% from baseline when compared with placebo, with no serious adverse effects.

Beyond the realm of chronic pain, cannabis has been shown to positively support individuals dealing with post-traumatic stress. It has demonstrated effectiveness at calming the often-debilitating side effects of inflammatory bowel disease, aka Crohn’s disease. Isolates from the cannabis plant have shown promise at treating “incurable” diseases such as Grave’s disease and brain cancer, and work better than traditional medications for Alzheimer’s disease. With so much evidence of profound medicinal value, legislation based on old systems of control will not long hold back the tide. There are simply too many health benefits to be obtained from the cannabis plant.

For additiona research on the medical benefits of cannabis, visit the GreenMedInfo database on the subject.

Resources

[1] https://www.sciencedaily.com/releases/2018/02/180213111508.htm

[2] Service Use Preceding Opioid-Related Fatality. Olfson, Wall, Wang, Crystal, Blanco. Am J Psychiatry. 2017 Nov 28:appiajp201717070808. doi: 10.1176/appi.ajp.2017.17070808.

[3] Institute of Medicine Report from the Committee on Advancing Pain Research, Care, and Education: Relieving Pain in America, A Blueprint for Transforming Prevention, Care, Education and Research. The National Academies Press, 2011. http://books.nap.edu/openbook.php?record_id=13172&page=1.

[4] IOM (Institute of Medicine) 2011. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education and Research, Washington, DC; The National Academies Press.

[5] Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. Gomes, Juurlink, Antoniou, Mamdani, Paterson, van den Brink. PLoS Med. 2017 Oct 3;14(10):e1002396. doi: 10.1371/journal.pmed.1002396. eCollection 2017 Oct.

Category:

Activism, Herbs, Inflammation, Pain Management, research, Treatment

ATA190 Cell Therapy – Could This Work for Some Lyme/MSIDS Patients?

https://multiplesclerosisnewstoday.com/2018/11/21/phase-1-trial-ata190-cell-therapy-shows-promise-treating-progressive-ms/

Phase 1 Trial of ATA190 Cell Therapy Shows Promise in Treating Progressive MS

November 21, 2018

by Patricia Inacio, PhD

In News.

Phase 1 Trial of ATA190 Cell Therapy Shows Promise in Treating Progressive MS

Atara Biotherapeutics’ investigational ATA190, a cell therapy that wipes out immune B-cells infected with the Epstein-Barr virus (EBV), led to neurological improvements and reduced symptoms in patients with primary and secondary progressive multiple sclerosis (MS), a Phase 1 trial shows.

The trial results were published in the Journal of Clinical Investigation Insightin a study titled “Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis.”

ATA190 is a T-cell immunotherapy that targets immune B-cells and plasma cells in the brain and spinal cord that have been infected with EBV. There is increasing evidence linking EBV infection with MS.

ATA190 is made from a patient’s own (autologous) immune cells, which are collected and modified in a lab to target the EBV-infected cells, then infused back into the patient’s blood. The goal is for the modified immune T-cells to recognize EBV-infected B-cells and kill them.

The Phase 1 trial (ACTRN12615000422527), conducted at the QIMR Berghofer Medical Research Institute and The University of Queensland, in Australia, evaluated the safety and efficacy of ATA190 as a treatment for progressive MS.

The study enrolled 10 patients — five with primary progressive MS (PPMS) and five with secondary progressive MS (SPMS). Patients had experienced progressive neurological deterioration due to MS for a mean of 10.1 years.

Participants were treated with four escalating doses of ATA190, administered intravenously over a period of eight weeks. The lowest and first dose was 5 million modified T-cells, followed by doses of 10, 15, and 20 million. Patients were followed for 27 weeks after the first infusion.

Results showed that ATA190 was well-tolerated, with no severe adverse events detected during the study. One patient experienced a potential treatment-related adverse event — dysgeusia, a distortion of the sense of taste.

Efficacy was measured by several parameters, including changes in the Expanded Disability Status Scale (EDSS) score, fatigue, as well as cognitive and other neurological parameters. Researchers also analyzed patients’ brains by magnetic resonance imaging (MRI) and tested their cerebrospinal fluid (CSF) — the liquid around the brain and spinal cord — for the presence of antibodies.

Seven of the 10 patients had improvements in neurological parameters — such as increased productivity, cognition, and word finding — accompanied by a reduction in symptoms. These benefits began two to 14 weeks after the first infusion.

Fatigue, one of the most disabling and hard-to-manage symptoms of MS, was reduced across the group — the median Fatigue Severity Scale score was lower at week 27 compared to the beginning of the study. This decrease, however, didn’t reach statistical significance.

Analysis of the CSF showed that levels of antibodies were reduced at the end of the study in four out of nine patients. Moreover, three of those four patients showed neurological improvements.

Patients received T-cells with different degrees of reactivity against EBV. Six patients who received T-cells with strong EBV reactivity showed clinical improvement; three of those experienced improvements in the EDSS score.

The other four patients received T-cells with weak EBV reactivity; of these, one showed improvement. None experienced a change in the EDSS score.

The team said that overall, the results show that the benefits seen are linked with T-cell effects.

“We previously presented promising initial ATA190 results in patients with progressive MS, and [now] the published results confirm our earlier observations,” Professors Michael Pender, of The University of Queensland, and Rajiv Khanna, coordinator of QIMR Berghofer Centre for Immunotherapy and Vaccine Development, the study’s lead authors, said in a press release.

“Findings from the study support growing evidence that targeting EBV-positive B-cells is a potential novel treatment modality for MS and merit additional investigation,” Pender and Khanna said.

“T-cell therapy targeting only EBV-infected B-cells is a treatment modality that could offer favorable safety and durable efficacy,” they wrote, adding that their work “sets the stage for further clinical trials with autologous and allogeneic EBV-targeted T-cell therapy in MS.”

Atara is developing another therapy, ATA188, to eliminate EBV-infected B-cells in the central nervous system. ATA188 uses immune cells from donors, not from the patients themselves — an allogenic therapy.

“We are also advancing an ongoing Phase 1 off-the-shelf, allogeneic ATA188 study in patients with progressive MS across clinical sites in the U.S. and Australia. We look forward to continued development of both programs, including our plans to initiate a randomized ATA190 MS study,” said Dietmar Berger, MD, PhD, global head of research and development of Atara Biotherapeutics.

___________________

**Comment**

I can’t help but think this therapy could help many Lyme/MSIDS patients. EBV is often a player in our illness and many have written about it:

https://madisonarealymesupportgroup.com/2018/04/25/ebv-protein-can-turn-on-genes-for-autoimmune-diseases/

https://madisonarealymesupportgroup.com/2017/11/04/24514/ (EBV – A Key Player in Chronic Illness)

Folks with Lyme/MSIDS have been misdiagnosed with EBV: https://madisonarealymesupportgroup.com/2017/04/11/diagnosed-with-ebv-had-lyme/ and others have it as well as tick-borne infections.

The involvement with numerous viruses is quite common in patients as well. https://madisonarealymesupportgroup.com/2018/10/30/study-shows-lyme-msids-patients-infected-with-many-pathogens-and-explains-why-we-are-so-sick/ For the first time, Garg et al. show a 85% probability for multiple infections including not only tick-borne pathogens but also opportunistic microbes such as EBV and other viruses.

https://madisonarealymesupportgroup.com/2018/04/21/neurological-lyme-disease-what-you-need-to-know/

“Once microbes start becoming active, inflammation increases and immune functions are further compromised, establishing what I call Chronic Immune Dysfunction (CID). In its weakened state, the immune system allows reactivation of viruses such as Epstein Barr virus (EBV), Cytomegalovirus (CMV), and other similar viruses — all of which most people harbor in their tissues. These viruses are commonly associated with neuroinflammation, and they tend to complicate the picture of LNB.”

This study shows elevated B-cells in those with untreated Lyme: https://www.frontiersin.org/articles/10.3389/fimmu.2018.01634/full

http://simmaronresearch.com/2018/09/post-treatment-lyme-disease-unmasked-immune-holes/ Mouse studies have shown that the Borrelia burgdorferi bacteria that cause Lyme disease hammer the B-cells….

Results

We herein identify plasmablasts as a key B cell population that correlates with resolution of Bb infection and Lyme disease in humans. The authors

They found that B-cells called plasmablasts were elevated prior to antibiotic treatment in patients who returned to health. Plasmablasts are activated B-cells which circulate for a time in the blood in response to an infection. The higher level of plasmablasts in the recovered patients suggests that these patients simply mounted a stronger immune response to the infection. That was kind of a no-brainer, but the strength of the study was that they were able to specify what part of our amazingly complex immune system the problem was in.

They also determined that the patients who returned to health also exhibited significantly greater clonal expansion: their activated B-cells produced more clones designed to target and get rid of the bacteria. Again, in retrospect, not a surprising finding, but one that does open up a possible treatment option that hasn’t previously been available.

Category:

Inflammation, Lyme, research, Treatment, Viruses

Four Essential Oils for Stopping Bartonella From Taking Over Your Brain

Four Essential Oils for Stopping Bartonella from Taking Over Your Brain

lava Published on October 30, 2018

Greg Lee (Founder of the Two Frogs Healing Center)

For people with neurological Bartonella symptoms of swelling and anxiety

My nephew invited us to his wedding in Hawaii. As we were booking our trip, the Kilauea volcano started spewing lava into residential neighborhoods. People had no other choice and had to evacuate as their homes and cars were burned by the spreading lava.

How is flowing lava similar to neurological Bartonella infections in people with Lyme disease?

Just like a hot lava eruption, a Bartonella infection can slowly burn through your body

Bartonella is a rod shaped, gram-negative bacteria that can be transmitted to humans via insect bites1, animal scratches and bites2, organ transplant3, needle sticks4, and blood transfusion5. At least thirteen different species of Bartonella are known to infect humans6. Bartonella has been shown to infect endothelial cells, macrophages, red blood cells7, and the lymphatic system8. Bartonella can spread through the bloodstream via the lymphatic system9. Bartonella manipulates the production of vascular endothelial growth factor10 (VEGF) and Interleukin-811 (IL-8) to make it easier for it to spread via new blood vessels through the skin and the body. Unfortunately, Bartonella can also infect the nervous system.

Bartonella has been detected in the cerebral spinal fluid of patients12

Patients with a Bartonella infection may present with multiple neurological symptoms including: confusion, encephalitis13, vision loss, neuroretinitis, optic neuropathy14, subarachnoid hemorrhage, cerebral embolism15, fever, vomiting, ataxia16, slurred speech, weakness17, convulsions18, chronic inflammatory demyelinating polyneuropathy19, depression, anxiety, mood swings, severe headaches, muscle spasms, decreased peripheral vision, diminished tactile sensation, and hallucinations20. Multiple patients have both Bartonella and Lyme disease in their nervous system21. Inflammation may play a role in Bartonella’s ability to spread into the brain.

Inflammatory compounds may help Bartonella spread into the nervous system

Patients diagnosed with Bartonella have elevated levels of IL-822, Interleukin-1023 (IL-10), and vascular endothelial growth factor24 (VEGF). Elevated levels of IL-825 and VEGF26 have been correlated with blood brain barrier increased permeability and dysfunction. Il-10 may help to protect the blood brain barrier27. Similarly, inflammatory compounds Interleukin-6 (IL-6), Interleukin- (IL-8), chemokine ligand 2 (CCL2), and CXCL13 are implicated in the spread of Lyme disease in the nervous system28. Another factor in persistent neurological infections may be due to drug resistant Bartonella strains that have been discovered.

Bartonella drug resistant strains have been discovered

Highly antibiotic resistant mutants of Bartonella bacilliformis have been found in a lab study29. Another study has found drug resistant forms of Bartonella henselae30.

Can essential oils help to reduce recurring neurological symptoms by preventing how Bartonella may spread into the nervous system?

Fortunately, there are four essential oils that lower the inflammatory compounds that Bartonella uses to spread through the body

In multiple studies, essential oils were effective at lowering inflammatory compounds and symptoms like anxiety that may be elevated in neurological Bartonella infections. Formulating these oils into microparticles called liposomes may help deliver these remedies deeper inside the brain. Many of these essential oils have been used safely for years in our food supply31. Formulating these essential oils into microparticles called liposomes may help them penetrate deeper inside of blood cells, endothelial cells and the nervous system where Bartonella likes to hide32.

Anti-Neurological Bartonella Essential Oil #1: Peppermint

In a mouse wound study, peppermint essential oil was effective at lowering VEGF and increasing IL-1033. Peppermint oil has had positive effects in reducing anxiety in human studies34. Do not apply peppermint oil undiluted to the feet of children under 12 years old, avoid large doses, it may cause heartburn, perianal burning, blurred vision, nausea and vomiting when taken internally. Peppermint essential oil use is contraindicated in children under 30 months old, and people should avoid the intake of peppermint oil with gallbladder disease, severe liver damage, gallstones, chronic heartburn35, and cases of cardiac fibrillation and in patients with a G6PD (Glucose-6-Phosphate Dehydrogenase) deficiency36. This oil is classified as Generally Recognized as Safe (GRAS) by the FDA37. Black cumin seed oil may also help to lower VEGF.

Anti-Neurological Bartonella Essential Oil #2: Black Cumin Seed

In lab studies, black cumin seed oil down regulated the expression of VEGF in endothelial cells38. In a rat study, this oil increased levels of tryptophan and reduced anxiety levels39. Black cumin seed oil is contraindicated in pregnancy and breastfeeding. It’s use is cautioned with diabetes medications, on hypersensitive, diseased or damaged skin, and in children under 2 years of age40. Mastic gum essential oil also lowers VEGF in experiments.

Anti-Neurological Bartonella Essential Oil #3: Mastic Gum

In a mouse lab study, mastic essential oil inhibited the release of VEGF41. In an outpatient study on Crohn’s disease, mastic gum decreased IL-6 and C-reactive protein (CRP)42. Citron essential oils lowered VEGF in a lab study.

Anti-Neurological Bartonella Essential Oil #4: Citron

In a lab study, citron essential oil lowered VEGF in endothelial cells43. These essential oils alone or in combination may help to reduce neurological symptoms caused by a spreading Bartonella infection in the nervous system.

Essential oils may help to reduce the spread of inflammation caused by neurological Bartonella infection

Similar to lava that is stopped by the cold waters of the ocean, essential oils that lower Bartonella inflammatory compounds may limit it’s spread in the brain and reduce neurological symptoms. Formulating these essential oils into microparticle liposomes may enhance their ability to penetrate into cells and stop Bartonella from invading the nervous system. Since these essential oils have cautions and contraindications on their use, work with a Lyme literate essential oil practitioner to develop a proper, safe, and effective strategy for your condition.

1 Billeter, S. A., M. G. Levy, B. B. Chomel, and E. B. Breitschwerdt. “Vector Transmission of Bartonella Species with Emphasis on the Potential for Tick Transmission.” Medical and Veterinary Entomology 22, no. 1 (March 2008): 1–15. https://doi.org/10.1111/j.1365-2915.2008.00713.x.

2 “Transmission | Bartonella | CDC.” Accessed July 22, 2016.http://www.cdc.gov/bartonella/transmission/.

3 Scolfaro, C., F. Mignone, F. Gennari, A. Alfarano, A. Veltri, R. Romagnoli, and M. Salizzoni. “Possible Donor-Recipient Bartonellosis Transmission in a Pediatric Liver Transplant.” Transplant Infectious Disease: An Official Journal of the Transplantation Society 10, no. 6 (December 2008): 431–33.https://doi.org/10.1111/j.1399-3062.2008.00326.x.

4 Breitschwerdt, Edward Bealmear. “Bartonellosis: One Health Perspectives for an Emerging Infectious Disease.” ILAR Journal 55, no. 1 (2014): 46–58. https://doi.org/10.1093/ilar/ilu015.

5 Núñez, M. Antonieta, Karla Contreras, M. Soledad Depix, Enrique Geoffroy, Nicolás Villagra, Sandra Mellado, and Ana M. Salinas. “[Prevalence of Bartonella henselae in blood donors and risk of blood transmission in Chile].” Revista Chilena De Infectologia: Organo Oficial De La Sociedad Chilena De Infectologia 34, no. 6 (December 2017): 539–43. https://doi.org/10.4067/S0716-10182017000600539.

6 Lamas, C., A. Curi, Mn Bóia, and Ers Lemos. “Human Bartonellosis: Seroepidemiological and Clinical Features with an Emphasis on Data from Brazil – a Review.” Memorias Do Instituto Oswaldo Cruz 103, no. 3 (May 2008): 221–35.

7 Breitschwerdt, Edward Bealmear. “Bartonellosis: One Health Perspectives for an Emerging Infectious Disease.” ILAR Journal 55, no. 1 (2014): 46–58. https://doi.org/10.1093/ilar/ilu015.

8 Choi, Alexander H., Michael Bolaris, Diana K. Nguyen, Eduard H. Panosyan, Joseph L. Lasky, and Gloria B. Duane. “Clinicocytopathologic Correlation in an Atypical Presentation of Lymphadenopathy with Review of Literature.” American Journal of Clinical Pathology 143, no. 5 (May 2015): 749–54.https://doi.org/10.1309/AJCPPSKWRX0GD8HJ.

9 Hong, Jiehua, Yan Li, Xiuguo Hua, Yajie Bai, Chunyan Wang, Caixia Zhu, Yuming Du, Zhibiao Yang, and Congli Yuan. “Lymphatic Circulation Disseminates Bartonella Infection Into Bloodstream.” The Journal of Infectious Diseases 215, no. 2 (January 15, 2017): 303–11. https://doi.org/10.1093/infdis/jiw526.

10 Kempf, V. A., B. Volkmann, M. Schaller, C. A. Sander, K. Alitalo, T. Riess, and I. B. Autenrieth. “Evidence of a Leading Role for VEGF in Bartonella Henselae-Induced Endothelial Cell Proliferations.”Cellular Microbiology 3, no. 9 (September 2001): 623–32.

11 McCord, Amy M., Sandra I. Resto-Ruiz, and Burt E. Anderson. “Autocrine Role for Interleukin-8 in Bartonella Henselae-Induced Angiogenesis.” Infection and Immunity 74, no. 9 (September 2006): 5185–90.https://doi.org/10.1128/IAI.00622-06.

12 Samarkos, Michael, Vasiliki Antoniadou, Aristeidis G. Vaiopoulos, and Mina Psichogiou. “Encephalopathy in an Adult with Cat-Scratch Disease.” BMJ Case Reports 2018 (March 5, 2018).https://doi.org/10.1136/bcr-2017-223647.

13 Samarkos, Michael, Vasiliki Antoniadou, Aristeidis G. Vaiopoulos, and Mina Psichogiou. “Encephalopathy in an Adult with Cat-Scratch Disease.” BMJ Case Reports 2018 (March 5, 2018).https://doi.org/10.1136/bcr-2017-223647.

14 Habot-Wilner, Zohar, Omer Trivizki, Michaella Goldstein, Anat Kesler, Shiri Shulman, Josepha Horowitz, Radgonde Amer, et al. “Cat-Scratch Disease: Ocular Manifestations and Treatment Outcome.” Acta Ophthalmologica, March 5, 2018. https://doi.org/10.1111/aos.13684.

15 Yuan, Y., M. Shen, and X. G. Gao. “[Presented with subarachnoid hemorrhage and then blood culture negative infective endocarditis: a case report and literature review].” Beijing Da Xue Xue Bao. Yi Xue Ban = Journal of Peking University. Health Sciences 49, no. 6 (December 18, 2017): 1081–86.

16 Barnafi, Natalia, Natalia Conca, Cecilia von Borries, Isabel Fuentes, Francisca Montoya, and Elisa Alcalde. “[Central nervous system infection by Bartonella henselae associated with a choroid plexus papilloma].” Revista Chilena De Infectologia: Organo Oficial De La Sociedad Chilena De Infectologia 34, no. 4 (August 2017): 383–88. https://doi.org/10.4067/s0716-10182017000400383.

17 Teoh, Laurence S G, Hamish H Hart, May Ching Soh, Jonathan P Christiansen, Hasan Bhally, Martin S Philips, and Dominic S Rai-Chaudhuri. “Bartonella Henselae Aortic Valve Endocarditis Mimicking Systemic Vasculitis.” BMJ Case Reports 2010 (October 21, 2010). https://doi.org/10.1136/bcr.04.2010.2945.

18 Balakrishnan, Nandhakumar, Marna Ericson, Ricardo Maggi, and Edward B. Breitschwerdt. “Vasculitis, Cerebral Infarction and Persistent Bartonella Henselae Infection in a Child.” Parasites & Vectors 9, no. 1 (2016): 254. https://doi.org/10.1186/s13071-016-1547-9.

19 Mascarelli, Patricia E, Ricardo G Maggi, Sarah Hopkins, B Robert Mozayeni, Chelsea L Trull, Julie M Bradley, Barbara C Hegarty, and Edward B Breitschwerdt. “Bartonella Henselae Infection in a Family Experiencing Neurological and Neurocognitive Abnormalities after Woodlouse Hunter Spider Bites.”Parasites & Vectors 6 (April 15, 2013): 98. https://doi.org/10.1186/1756-3305-6-98.

20 Breitschwerdt, Edward B., Patricia E. Mascarelli, Lori A. Schweickert, Ricardo G. Maggi, Barbara C. Hegarty, Julie M. Bradley, and Christopher W. Woods. “Hallucinations, Sensory Neuropathy, and Peripheral Visual Deficits in a Young Woman Infected with Bartonella Koehlerae ▿.” Journal of Clinical Microbiology49, no. 9 (September 2011): 3415–17. https://doi.org/10.1128/JCM.00833-11.

21 Podsiadły, Edyta, Tomasz Chmielewski, and Stanisława Tylewska-Wierzbanowska. “Bartonella Henselae and Borrelia Burgdorferi Infections of the Central Nervous System.” Annals of the New York Academy of Sciences 990 (June 2003): 404–6.

22 McCord, Amy M., Sandra I. Resto-Ruiz, and Burt E. Anderson. “Autocrine Role for Interleukin-8 in Bartonella Henselae-Induced Angiogenesis.” Infection and Immunity 74, no. 9 (September 2006): 5185–90.https://doi.org/10.1128/IAI.00622-06.

23 Huarcaya, Erick, Ciro Maguina, Ivan Best, Nelson Solorzano, and Lawrence Leeman. “Immunological Response in Cases of Complicated and Uncomplicated Bartonellosis during Pregnancy.” Revista Do Instituto De Medicina Tropical De Sao Paulo 49, no. 5 (October 2007): 335–37.

24 Kempf, V. A., B. Volkmann, M. Schaller, C. A. Sander, K. Alitalo, T. Riess, and I. B. Autenrieth. “Evidence of a Leading Role for VEGF in Bartonella Henselae-Induced Endothelial Cell Proliferations.”Cellular Microbiology 3, no. 9 (September 2001): 623–32.

25 Kossmann, T., P. F. Stahel, P. M. Lenzlinger, H. Redl, R. W. Dubs, O. Trentz, G. Schlag, and M. C. Morganti-Kossmann. “Interleukin-8 Released into the Cerebrospinal Fluid after Brain Injury Is Associated with Blood-Brain Barrier Dysfunction and Nerve Growth Factor Production.” Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 17, no. 3 (March 1997): 280–89. https://doi.org/10.1097/00004647-199703000-00005.

26 Zhang, Zheng Gang, Li Zhang, Quan Jiang, Ruilan Zhang, Kenneth Davies, Cecylia Powers, Nicholas van Bruggen, and Michael Chopp. “VEGF Enhances Angiogenesis and Promotes Blood-Brain Barrier Leakage in the Ischemic Brain.” Journal of Clinical Investigation 106, no. 7 (October 1, 2000): 829–38.

27 Lin, Ronggui, Fei Chen, Shi Wen, Tianhong Teng, Yu Pan, and Heguang Huang. “Interleukin-10 Attenuates Impairment of the Blood-Brain Barrier in a Severe Acute Pancreatitis Rat Model.” Journal of Inflammation (London, England) 15 (2018): 4. https://doi.org/10.1186/s12950-018-0180-0.

28 Ramesh, Geeta, Peter J. Didier, John D. England, Lenay Santana-Gould, Lara A. Doyle-Meyers, Dale S. Martin, Mary B. Jacobs, and Mario T. Philipp. “Inflammation in the Pathogenesis of Lyme Neuroborreliosis.”The American Journal of Pathology 185, no. 5 (May 2015): 1344–60.https://doi.org/10.1016/j.ajpath.2015.01.024.

29 Gomes, Cláudia, Sandra Martínez-Puchol, Lidia Ruiz-Roldán, Maria J. Pons, Juana del Valle Mendoza, and Joaquim Ruiz. “Development and Characterisation of Highly Antibiotic Resistant Bartonella BacilliformisMutants.” Scientific Reports 6 (September 26, 2016): 33584. https://doi.org/10.1038/srep33584.

30 Biswas, Silpak, Ricardo G. Maggi, Mark G. Papich, and Edward B. Breitschwerdt. “Molecular Mechanisms of Bartonella Henselae Resistance to Azithromycin, Pradofloxacin and Enrofloxacin.” Journal of Antimicrobial Chemotherapy 65, no. 3 (March 1, 2010): 581–82. https://doi.org/10.1093/jac/dkp459.

31 Hyldgaard, Morten, Tina Mygind, and Rikke Louise Meyer. “Essential Oils in Food Preservation: Mode of Action, Synergies, and Interactions with Food Matrix Components.” Frontiers in Microbiology 3 (January 25, 2012). https://doi.org/10.3389/fmicb.2012.00012.

32 Sherry, Mirna, Catherine Charcosset, Hatem Fessi, and Hélène Greige-Gerges. “Essential Oils Encapsulated in Liposomes: A Review.” Journal of Liposome Research 23, no. 4 (December 2013): 268–75.https://doi.org/10.3109/08982104.2013.819888.

33 Modarresi, Mohammad, Mohammad-Reza Farahpour, and Behzad Baradaran. “Topical Application of Mentha Piperita Essential Oil Accelerates Wound Healing in Infected Mice Model.” Inflammopharmacology, July 6, 2018. https://doi.org/10.1007/s10787-018-0510-0.

34 Stea, Susanna, Alina Beraudi, and Dalila De Pasquale. “Essential Oils for Complementary Treatment of Surgical Patients: State of the Art.” Evidence-Based Complementary and Alternative Medicine : ECAM 2014 (2014). https://doi.org/10.1155/2014/726341.

35 “Peppermint Safety Info | National Association for Holistic Aromatherapy.” Accessed April 1, 2017. http://naha.org/naha-blog/peppermint-safety-info/.

36 Tisserand, Robert, and Rodney Young. Essential Oil Safety: A Guide for Health Care Professionals. 2 edition. Edinburgh: Churchill Livingstone, 2013.

37 “CFR – Code of Federal Regulations Title 21.” Accessed October 28, 2018.https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=182.20.

38 M. Baharetha, Hussein, Zeyad Nassar, Abdalrahim Aisha, Abd Kadir M.O, Zhari Ismail, and Amin Malik Shah Abdul Majid. “Essential Oil of Nigella Sativa Inhibits Angiogenesis via Down-Regulation of VEGF Expression,” 2015. https://doi.org/10.4172/2375-4273.C1.009.

39 Perveen, Tahira, Saida Haider, Sumera Kanwal, and Darakhshan Jabeen Haleem. “Repeated Administration of Nigella Sativa Decreases 5-HT Turnover and Produces Anxiolytic Effects in Rats.”Pakistan Journal of Pharmaceutical Sciences 22, no. 2 (April 2009): 139–44.

40 Tisserand, Robert, and Rodney Young. Essential Oil Safety: A Guide for Health Care Professionals. 2 edition. Edinburgh: Churchill Livingstone, 2013. p. 793.

41 Loutrari, Heleni, Sophia Magkouta, Anastasia Pyriochou, Vasiliki Koika, Fragiskos N. Kolisis, Andreas Papapetropoulos, and Charis Roussos. “Mastic Oil from Pistacia Lentiscus Var. Chia Inhibits Growth and Survival of Human K562 Leukemia Cells and Attenuates Angiogenesis.” Nutrition and Cancer 55, no. 1 (2006): 86–93. https://doi.org/10.1207/s15327914nc5501_11.

42 Kaliora, Andriana C, Maria G Stathopoulou, John K Triantafillidis, George VZ Dedoussis, and Nikolaos K Andrikopoulos. “Chios Mastic Treatment of Patients with Active Crohn’s Disease.” World Journal of Gastroenterology : WJG 13, no. 5 (February 7, 2007): 748–53. https://doi.org/10.3748/wjg.v13.i5.748.

43 “Effects of Citron Essential Oils on Normal Human Epidermal Keratinocytes Stimulated with Vitamin D3 and TNF-A.” Journal of the American Academy of Dermatology 76, no. 6 (June 1, 2017): AB110.https://doi.org/10.1016/j.jaad.2017.04.436.

___________________

For more on essential oils: https://madisonarealymesupportgroup.com/2017/10/13/oregano-cinnamon-and-clove-found-to-have-high-anti-persister-activity-for-bb/

https://madisonarealymesupportgroup.com/2018/10/26/essential-oils-as-treatment-against-lyme-disease/

https://madisonarealymesupportgroup.com/2018/08/02/can-these-essential-oils-help-lyme-patients-overcome-chronic-candida/

I have personally used 1-2 drops of DMSO in a capsule with EO’s instead of the liposomal form with success. I can smell/taste the DMSO so I know even at that low dose it’s gone systemic, driving the EO’s deep into the body, yet, it can’t be smelled by others at this dose! Also, I use black seed oil as a carrier as well, which is listed as #2 in the article. If you haven’t read about the usage of DMSO, please go here and learn: https://madisonarealymesupportgroup.com/2018/03/02/dmso-msm-for-lyme-msids/

More on Bartonella treatment: https://madisonarealymesupportgroup.com/2016/01/03/bartonella-treatment/

Category:

Bartonella, Herbs, Inflammation, Psychological Aspects, research, Treatment

Diagnosing & Treating Autoimmune Encephalitis in Patients with Persistent Lyme Symptoms

Approx. 47 Min.

Dr. Frid: Diagnosing and Treating Infectious Induced AE in Patients with Persistent Lyme Symptoms

Dr. Elena Frid talk Diagnosing and Treating Infections Induced Autoimmune Encephalitis in Patient’s with Persistent Lyme Symptoms to physicians and patients at the Central Mass Lyme conference

_________________

More with Dr. Frid: https://madisonarealymesupportgroup.com/2018/03/14/dr-frid-children-lyme/

https://madisonarealymesupportgroup.com/2017/11/24/dr-frid-lyme-parkinsons-autoimmunity/

https://madisonarealymesupportgroup.com/2017/08/09/meet-the-lyme-disease-experts-dr-elena-frid-and-more/

https://madisonarealymesupportgroup.com/2018/04/17/dr-frid-mary-beth-pfeiffer-on-fox5/

More on Lyme encephalitis: https://madisonarealymesupportgroup.com/2018/07/03/lyme-meningoencephalitis-masquerading-as-normal-pressure-hydrocephalus/

https://madisonarealymesupportgroup.com/2017/10/30/tick-borne-encephalitis-found-in-serbian-dogs-horses-wild-boar-and-roe-deer/

https://madisonarealymesupportgroup.com/2017/10/01/panspandas-steroids-autoimmune-disease-lymemsids-the-need-for-medical-collaboration/ There is often involvement with Lyme/MSIDS in both Autism and PANS. Here we see a story of Patrik, who was diagnosed with Lyme Disease which then morphs into Autoimmune encephalopathy. It took 10 years and 20 doctors to obtain the Lyme disease diagnosis behind his autoimmune condition.

How many people are slipping through this crack?

This pivotal study shows the complex issue of coinfections and the Lyme persister organism in lowering patients’ immune system thereby opening the door to opportunistic infections which can cause encephalopathy: https://madisonarealymesupportgroup.com/2018/10/30/study-shows-lyme-msids-patients-infected-with-many-pathogens-and-explains-why-we-are-so-sick/

Category:

Inflammation, Lyme, Psychological Aspects, Treatment, Viruses

Madison Area Lyme Support Group

Archive for the ‘Inflammation’ Category